SmithKline/Bristol-Myers
Executive Summary
IND for H2 receptor-antagonist BMY 25368, under development by SmithKline, transferred back to Bristol-Myers. The potential "son of Tagamet" was a part of June 1987 swap that involved the granting of U.S. and Canadian comarketing rights to Bristol for OTC cimetidine. SmithKline says it is discussing "the entire situation" with Bristol-Myers....
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.